Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Antibiotic susceptibility and serotype distribution in Streptococcus pneumoniae circulating in Italy: results of the SEMPRE surveillance study (2000-2002).

Marchese A, Gualco L, Cochetti I, Montanari MP, Speciale AM, Musumeci SR, Varaldo PE, Nicoletti G, Schito GC.

Int J Antimicrob Agents. 2005 Aug;26(2):138-45.

PMID:
16024234
2.

Frequency of detection of picornaviruses and seven other respiratory pathogens in infants.

Legg JP, Warner JA, Johnston SL, Warner JO.

Pediatr Infect Dis J. 2005 Jul;24(7):611-6.

PMID:
15999002
3.
4.

The Sentinel Project: an update on the prevalence of antimicrobial resistance in community-acquired respiratory Streptococcus pneumoniae and Haemophilus spp. in Italy.

Marchese A, Ardito F, Fadda G, Fontana R, Lo Cascio G, Nicoletti G, Speciale AM, Schito GC.

Int J Antimicrob Agents. 2005 Jul;26(1):8-12.

PMID:
15967638
5.

Community-acquired pneumonia in children: quantifying the burden on patients and their families including decrease in quality of life.

Shoham Y, Dagan R, Givon-Lavi N, Liss Z, Shagan T, Zamir O, Greenberg D.

Pediatrics. 2005 May;115(5):1213-9.

PMID:
15867027
6.

Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine.

Haddy RI, Perry K, Chacko CE, Helton WB, Bowling MG, Looney SW, Buck GE.

Pediatr Infect Dis J. 2005 Apr;24(4):320-3.

PMID:
15818291
7.

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.

Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA; Gambian Pneumococcal Vaccine Trial Group.

Lancet. 2005 Mar 26-Apr 1;365(9465):1139-46. Erratum in: Lancet. 2005 Jul 2-8;366(9479):28.

PMID:
15794968
8.

Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants.

Esposito S, Pugni L, Bosis S, Proto A, Cesati L, Bianchi C, Cimino C, Mosca F, Principi N.

Vaccine. 2005 Feb 25;23(14):1703-8.

PMID:
15705475
9.

Acquisition of Streptococcus pneumoniae and nonspecific morbidity in infants and their families: a cohort study.

Sleeman KL, Daniels L, Gardiner M, Griffiths D, Deeks JJ, Dagan R, Gupta S, Moxon ER, Peto TE, Crook DW.

Pediatr Infect Dis J. 2005 Feb;24(2):121-7.

PMID:
15702039
10.

Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age.

Käyhty H, Ahman H, Eriksson K, Sörberg M, Nilsson L.

Pediatr Infect Dis J. 2005 Feb;24(2):108-14.

PMID:
15702037
11.

Resistance trends in Streptococcus pneumoniae (PROTEKT years 1-3 [1999-2002]).

Schito GC.

J Chemother. 2004 Dec;16 Suppl 6:19-33. Review. No abstract available.

PMID:
15690683
12.

Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.

Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J; Massachusetts Department of Public Health Epidemiologists.

Pediatr Infect Dis J. 2005 Jan;24(1):17-23.

PMID:
15665705
13.

Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults.

Shafinoori S, Ginocchio CC, Greenberg AJ, Yeoman E, Cheddie M, Rubin LG.

Pediatr Infect Dis J. 2005 Jan;24(1):10-6.

PMID:
15665704
14.

Studies in otitis media: Children's Hospital of Pittsburgh-University of Pittsburgh progress report--2004.

Bluestone CD.

Laryngoscope. 2004 Nov;114(11 Pt 3 Suppl 105):1-26. Review.

PMID:
15514559
15.

Population-based impact of pneumococcal conjugate vaccine in young children.

Poehling KA, Lafleur BJ, Szilagyi PG, Edwards KM, Mitchel E, Barth R, Schwartz B, Griffin MR.

Pediatrics. 2004 Sep;114(3):755-61.

PMID:
15342850
16.

The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children.

Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM.

Pediatr Infect Dis J. 2004 Aug;23(8):732-8.

PMID:
15295223
17.

Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine.

Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR.

Pediatr Infect Dis J. 2004 Aug;23(8):726-31.

PMID:
15295222
18.

A role for Streptococcus pneumoniae in virus-associated pneumonia.

Madhi SA, Klugman KP; Vaccine Trialist Group.

Nat Med. 2004 Aug;10(8):811-3. Epub 2004 Jul 11.

19.

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.

Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B.

Pediatr Infect Dis J. 2004 Jun;23(6):485-9.

PMID:
15194827
20.

Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children.

Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, Kauppila J, Leinonen M, McCracken GH Jr.

Pediatrics. 2004 Apr;113(4):701-7.

PMID:
15060215

Supplemental Content

Support Center